National Bank of Canada
AKRO

National Bank of Canada’s Akero Therapeutics AKRO Stock Holding History

National Bank of Canada’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-59,000
Closed -$3.23M – 2702
2022
Q4 		$3.23M Buy
+59,000
New +$2.53M 0.01% 748

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

National Bank of Canada's AKRO Position: Q1 2023 in Review

National Bank of Canada sold out of Akero Therapeutics (AKRO) in Q1 2023, closing a stake of 59,000 shares — an estimated $3.23M sold.

National Bank of Canada first reported a position in AKRO in Q4 2022 and held it in 1 quarter. The position peaked at $3.23M in Q4 2022. 156 funds tracked by Wall St. Rank hold AKRO as of Q1 2023.

  • National Bank of Canada reported no remaining Akero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • National Bank of Canada sold 59,000 Akero Therapeutics shares in Q1 2023, an estimated $3.23M.
  • National Bank of Canada first reported a position in Akero Therapeutics in Q4 2022 and held it in 1 quarter.
  • National Bank of Canada's Akero Therapeutics position peaked at $3.23M in Q4 2022.
  • 156 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2023.

Based on National Bank of Canada's 13F filing for Q1 2023, filed 12 Apr 2023.